Agenda & Webinars (2021)

View the agenda (as pdf).

Alzheimer’s Association Impact on Global Research: Fueling Discovery at Any Given Moment.
Alzheimer’s Genes to Drugs: Getting the Translation Right

Margaret A. Pericak-Vance, Ph.D.;
Maria Carrillo, Ph.D.;
Francis Collins, M.D., Ph.D.

Genetics: Discovery and Risk Scores

Elizabeth Blue, Ph.D.

Keynote: How Can the Genetic Architecture of AD Inform Disease Mechanism?

Julie Williams, B.Sc., Ph.D.

APOE4, Ancestry and Clinical Implications

Jeffery Vance, M.D., Ph.D.

Polygenic Risk Scores for AD: Applications and Optimization for Diverse Populations

Giuseppe Tosto, M.D., Ph.D.

Endophenotypes Provide Novel Insight into the Genetics of Alzheimer’s Disease

Sudha Seshadri, M.D.

Human Genetics of Cardiometabolic Disease

Amit Khera, M.D., M.Sc.

Genetics in Drug Discovery: Cognitive Decline in Alzheimer’s Disease

David Pulford, Ph.D.

Introduction – Genes and the Environment Across Populations

Jonathan Haines, Ph.D.

The Epidemiology and Genetics of AD in Africa

Rufus Akinyemi, M.B.B.S., M.Sc., Ph.D., M.W.A.C.P., F.M.C.P.

The Comorbid Effects of Cerebrovascular Disease and Genetic Risk in AD

Richard Mayeux, M.D., M.Sc.

Vascular Risk Factors and Cognitive Decline in Diverse Populations

Ralph Sacco, M.D, M.S., F.A.H.A., F.A.A.N.

Modifiable Risk Factors for ADRD

Kristine Yaffe, M.D.

Harmonized Diagnostic Assessment: The Longitudinal Aging Study in India

Jinkook Lee Ph.D.

Sex Differences in Alzheimer’s Disease and Implications for Precision Medicine

Eden Martin, Ph.D.

Introduction – Biomarkers and Endophenotypes

Richard Mayeux, M.D., M.Sc.

TREM2 and sTREM2 Signalling in Microglia

Peter St George-Hyslop, M.D.

Update on Fluid Biomarkers for Neurodegenerative Diseases

Henrik Zetterberg, M.D., Ph.D

Measuring Phosphorylated Tau in Blood as a Biomarker for Alzheimer’s Disease

Jeff Dage, Ph.D.

Imaging and Blood Biomarkers in the Colombian Kindred with Autosomal Dominant AD

Yakeel Quiroz-Gaviria, Ph.D.

Modulation of Protective Microglial Activities in Alzheimer’s Disease

Christian Haass, Ph.D.

Mechanistic and Dynamic Systems Modeling of Alzheimer’s Disease Across Lifespan

Nathan Price, Ph.D.

Brain Proteomics Therapeutic Target and Biomarker Discovery

Allan Levey, M.D., Ph.D.

Gut Microbiome Alterations Associated with Alzheimer’s Disease

Beau Ances, M.D. M.Sc., Ph.D.

Introduction – Towards Precision Medicine

Eric McDade, D.O.

Keynote: Multi-Scale Data Integration to Transition Genetic Associations to Therapeutics

Phil De Jager, M.D., Ph.D.

Bridging the Gap Between Genetic Research and Prevention

Cornelia Van Duijn, Ph.D.

Genetic Counseling and Testing for Alzheimer’s Disease: A View from the Trenches

Robin Bennett, M.S., C.G.C., Ph.D.

From Gene Discovery to Clinical Translation: Ethical and Social Implications

Stephanie Malia Fullerton, D.Phil.

Understanding Neuroimmune Biology and Targets in AD Through MODEL-AD and TREAT-AD

Bruce Lamb, Ph.D.

Finding Novel Targets Via Antibody Repertoire Analysis of Resilient Patients

Ralph Minter, Ph.D., F.R.S.B.

Introduction – Therapeutic Targets

Carlos Cruchaga, Ph.D

Keynote: Using Genomics to Identify Therapeutic Targets for Non-Alzheimer’s Dementias

Brian Traynor, M.D., Ph.D.

Targeting Innate Immunity in Alzheimer’s Disease

Rudy Tanzi, Ph.D.

Genetically-Defined Therapies for Neurodegenerative Disorders

Hervé Rhinn, Ph.D.

Pathways to Endosome Dysfunction in Alzheimer’s Disease

Ralph Nixon, M.D., Ph.D.

Omics Analysis to Small Molecule Drug Development: RAB10 and NEK7

John “Keoni” S.K. Kauwe III, Ph.D.

Artificial Intelligence Approaches for Discovery in Alzheimer’s Disease Biobanks

Paul Thompson, Ph.D.

Targeting Pre-Symptomatic AD Using Autosomal Dominant AD

Eric McDade, D.O.

Maximizing the Application of Human Genetics for AD Drug Discovery

Janna Hutz, Ph.D.

AAIC Symposium Summary

Badri Vardarajan, Ph.D.